- Home
- MVIS vs TCRX Comparison
MVIS vs TCRX Comparison
Compare MVIS & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVIS
- TCRX
- Stock Information
- Founded
- MVIS 1993
- TCRX 2018
- Country
- MVIS United States
- TCRX United States
- Employees
- MVIS N/A
- TCRX N/A
- Industry
- MVIS Industrial Machinery/Components
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- MVIS Technology
- TCRX Health Care
- Exchange
- MVIS Nasdaq
- TCRX Nasdaq
- Market Cap
- MVIS 234.3M
- TCRX 257.5M
- IPO Year
- MVIS 1996
- TCRX 2021
- Fundamental
- Price
- MVIS $0.89
- TCRX $4.41
- Analyst Decision
- MVIS Hold
- TCRX Strong Buy
- Analyst Count
- MVIS 2
- TCRX 5
- Target Price
- MVIS $3.00
- TCRX $11.40
- AVG Volume (30 Days)
- MVIS 2.1M
- TCRX 261.6K
- Earning Date
- MVIS 11-07-2024
- TCRX 11-12-2024
- Dividend Yield
- MVIS N/A
- TCRX N/A
- EPS Growth
- MVIS N/A
- TCRX N/A
- EPS
- MVIS N/A
- TCRX N/A
- Revenue
- MVIS $8,147,000.00
- TCRX $9,362,000.00
- Revenue This Year
- MVIS $24.78
- TCRX N/A
- Revenue Next Year
- MVIS $322.28
- TCRX $3.10
- P/E Ratio
- MVIS N/A
- TCRX N/A
- Revenue Growth
- MVIS 277.53
- TCRX N/A
- 52 Week Low
- MVIS $0.83
- TCRX $3.73
- 52 Week High
- MVIS $2.98
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- MVIS 32.02
- TCRX 34.37
- Support Level
- MVIS $1.03
- TCRX $5.03
- Resistance Level
- MVIS $1.06
- TCRX $6.23
- Average True Range (ATR)
- MVIS 0.06
- TCRX 0.43
- MACD
- MVIS -0.01
- TCRX -0.05
- Stochastic Oscillator
- MVIS 0.00
- TCRX 5.22
About MVIS MicroVision Inc.
Microvision Inc is engaged in developing a lidar sensor to be used in automotive safety and autonomous driving applications. Its lidar sensor uses laser beam scanning (LBS) technology, which is based on systems that include micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms, and software. The company has also developed solutions for Augmented Reality, Interactive Displays, and Consumer Lidars.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.